About This Fund
BrightEdge Fund is the impact investment and venture capital arm of the American Cancer Society (ACS), one of the oldest and largest voluntary health organizations in the United States. Operating under the ACS BrightEdge brand, the fund makes equity investments in for-profit, early-stage companies developing breakthrough cancer-focused therapeutics, diagnostics, devices, and enabling technologies across the full cancer care continuum. The fund's mandate bridges the gap between philanthropic capital and venture capital, deploying donor-backed investment capital to support innovations that deliver simultaneous scientific, social, and sustainable returns.
BrightEdge Fund targets companies addressing unmet needs in cancer detection, treatment, patient support, and health equity. The investment strategy emphasizes translating promising scientific discoveries into actionable, scalable commercial solutions with durable impact potential. Portfolio decisions leverage the American Cancer Society's deep institutional expertise in oncology, its nationwide patient network, and its relationships with leading academic medical centers and clinical research institutions. The fund has made a total of 13 investments and operates with an active portfolio spanning oncology therapeutics, digital health, diagnostics, and cancer care technology.
The fund's investor base is composed of founding philanthropic members — including Lyda Hill Philanthropies, Resonance Philanthropies, and Wood Next Foundation — alongside the ACS itself. BrightEdge is led by a dedicated team of 16 investment, innovation, and operations professionals, supported by the broader ACS platform. The fund publishes an annual report and maintains public disclosure of its investments through the ACS's website, offering greater transparency than most impact vehicle of this type.